Paragraf partnership feels like more than just a routine announcement. Paragraf is one of the only companies in the world producing actual graphene-based electronics at scale — not lab fluff. The fact that Archer’s quantum and biochip projects now have access to Paragraf’s foundry capability is huge. It means real materials, real devices, and potentially faster timelines. What stands out to me: Archer doesn’t have to reinvent the graphene wheel — they can now plug into Paragraf’s existing infrastructure. This helps them focus on their IP and architecture instead of getting bogged down in materials science hurdles. Paragraf wouldn’t partner unless they saw serious potential in Archer’s tech. If this helps move CQ and the biochip from test rigs to more production-ready prototypes, it could unlock actual commercial value. DYOR on paragraf and particularly Simon Thomas.
AXE Price at posting:
24.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)